

1

2 **Limits and opportunities of SARS-CoV-2 antigen rapid tests – an experience based**  
3 **perspective**

4 Jessica Lüsebrink<sup>1,a</sup>, Oliver Schildgen<sup>1</sup>, and Verena Schildgen<sup>1, a,#</sup>

5

6 1. All Authors' affiliation: Kliniken der Stadt Köln gGmbH, Institut für Pathologie, Klinikum  
7 der Privaten Universität Witten/Herdecke, Ostmerheimer Str. 200, 51109 Köln

8 a) authors contributed equally to this manuscript

9

10 # Send correspondence to:

11 Priv.-Doz.in. Dr. rer. nat. Verena Schildgen

12 Kliniken der Stadt Köln gGmbH

13 Klinikum der Privaten Universität Witten/Herdecke

14 Institut für Pathologie

15 Ostmerheimer Str. 200

16 D-51109 Köln (Cologne)

17 Germany

18 Tel.: +49(0)221-890718887

19 Fax.: +40(0)221-89073542

20 E-Mail: [schildgen@kliniken-koeln.de](mailto:schildgen@kliniken-koeln.de)

21 [verena.schildgen@uni-wh.de](mailto:verena.schildgen@uni-wh.de)

22

23

## 24 **Abstract**

25 Due to the currently increasing case numbers of SARS-CoV-2 infections worldwide there is  
26 an increasing need for rapid diagnostic devices in addition to existing PCR-capacities.  
27 Therefore, rapid antigen assays including lateral flow assays are discussed as an alternative  
28 method. In comparison to an established RT-PCR protocol, however the novel lateral flow  
29 assay unfortunately lowered the expectations set in these assays.

30

## 31 **Brief Communication**

32 In December 2019 the public became aware of the new betacoronavirus SARS-CoV-2 due to  
33 an outbreak in Wuhan, China (1). Very soon it turned out that spreading of the virus cannot  
34 be prevented and Covid-19 was declared a pandemic in March 2020  
35 (<https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic>). In order to minimize the  
36 risk of infection different undirected as well as targeted tracking strategies were developed,  
37 whose success is dependent on extensive testing of the largest possible number of people  
38 (2). For SARS-CoV-2 detection different PCRs are used in routine diagnostic. Although these  
39 PCRs are actually the “gold” standard (3), valuable time passes until the result is available  
40 (<https://www.nytimes.com/2020/08/04/us/virus-testing-delays.html>). Since it was shown that  
41 rapid antibody screenings are not suitable to evaluate chains of infection or their interruption,  
42 other kinds of rapid on-site tests are needed to perform the requested mass testing.  
43

44 One of these is the BIOCREDIT COVID-19 Ag test of RapiGENJNC (Korea). This lateral flow  
45 test is based on immunochromatography and shows SARS-CoV-2 antigen presence by  
46 staining with colloid gold conjugate as a black test line. According to the manufacturer’s  
47 instruction it should support early diagnosis of Covid-19 infections in patients with clinical  
48 symptoms. Sampling should be performed in the nasopharynx with the supplied swab, but  
49 UTM/VTM media is also appropriate if diluted 1:2 with assay buffer. Moreover it has been  
50 shown that specimen other than nasopharyngeal swaps have comparable diagnostic  
51 sensitivity (4)(5). For this reason we tested a pilot sample panel of 11 BALFs  
52 (bronchoalveolar lavage fluid) and 70 throat washing samples with confirmed PCR results  
53 (RealStar® SARS-CoV-2 RT-PCR Kit, Altona, Germany), as well as 9 throat washes invalid  
54 by PCR. First, we evaluated if the BIOCREDIT assay is able to detect SARS-CoV-2 Ag in  
55 these specimens. For this reason we applied 150 µl of either diluted (d) or original (o)  
56 specimen on the device and checked for the presence of the red control line (C) and the  
57 black test line (T). This pilot approach showed that the specimens used allow a proper test

58 performance and that SARS-CoV-2 antigen can principally be detected in throat washes (I  
59 and II) and BALF (III) (figure 1).


60 The analysis of the complete test cohort reveals an overall sensitivity of 29.4% and an overall  
61 specificity of 86.7% (figure 2A). This means a PPV of 79.0% and a NPV of 41.9%. Next, we  
62 analyzed test sensitivity and specificity in 55 samples of confirmed symptomatic (58.2%) and  
63 asymptomatic (41.8%) individuals with regard to the respective PCR result, which leads to  
64 sensitivity values of 22.2% (asymptomatic) and 30% (symptomatic) with specificities of  
65 92.9% (asymptomatic) and 76.9% (symptomatic) (figure 2B & C). Regarding the BALF  
66 specimens the test shows 54.6% sensitivity, but 100% specificity with a PPV of 100% and a  
67 NPV of 28.6% (figure 2B & C). These results damp the expectation that PCR invalid samples  
68 could reliably be analyzed with the rapid antigen test, although three of nine PCR invalid  
69 samples are SARS-CoV-2 antigen positive, whereas 6 did not show antigen presence.

70 When checking any correlation of viral RNA load and presence of SARS-CoV-2 antigen we  
71 were able to monitor two asymptomatic individuals, who were PCR positive for more than  
72 five weeks before recovering in week six. Ct values ranged from 23.8 to 35.2 in patient A  
73 (blue data series) and from 27.9 to 34.3 in patient B (green data series), but SARS-CoV-2  
74 antigen was only detected in three samples with Ct values >30 (figure 3). The fact that  
75 SARS-CoV-2 antigen is detected in samples of individuals ranging from asymptomatic +  
76 PCR negative and symptomatic + PCR negative, to asymptomatic + PCR positive and  
77 symptomatic + PCR positive (figure 2), suggest that this test is not suitable for routine  
78 diagnostics as long as the complex relationships between viral RNA load, SARS-CoV-2  
79 antigen detection, and clinical symptoms remain unsolved.

80 Regarding the correlation of PCR and the BIOCREREDIT SARS-CoV-2 antigen test, the  
81 significance of the BIOCREREDIT test cannot be evaluated only based on RNA presence,  
82 because both the intra-individual and the inter-individual course of viral replication kinetics  
83 with prolonged viral RNA shedding and the unknown quality and quantity of accompanying  
84 antigen, as also observed in the present study, make it impossible to estimate the diagnostic  
85 utility of rapid antigen tests. Moreover, the limited information on host and viral factors  
86 influencing shedding of SARS-CoV-2 antigens and their correlation to infectious viruses  
87 impede any prognosis on infectivity. So far it also remains unclear if further common  
88 phenomena such as defective interfering particles, antigen drift or antigen shift occur during  
89 the current pandemic influencing the assay performance of any SARS-CoV-2 test.

90 Although it seems that exclusive antigen tests actually cannot replace PCR assays, they  
91 could additionally be used to gain deeper insights into infectivity and the course of infection  
92 to develop more advanced testing strategies.


93



94

95 **Figure 1: SARS-CoV-2 antigen detection.** To evaluate the suitability of specimen others  
96 than nasopharyngeal swabs 150µl of two PCR positive throat washes (I: Ct<sub>E-Gen</sub>=15,6, Ct<sub>S-Gen</sub>=14,8;  
97 II: Ct<sub>E-Gen</sub>=14,7, Ct<sub>S-Gen</sub>=14,9) and one BALF (III: Ct<sub>E-gen</sub>=13,1, Ct<sub>S-Gen</sub>=12,6) were  
98 used. The BIOCREREDIT Covid-19 Ag test detected SARS-CoV-2 antigen in all samples, but  
99 dilution in assay buffer (d) decreases sensitivity compared to original fluid (o). As shown by  
100 the control line the specimens allowed a proper test performance and did not contain any  
101 inhibitory substances. d=1:2 diluted, o= original


102



103

104 **Figure 2: Specificity and sensitivity of SARS-CoV-2 antigen detection in PCR tested**  
105 **specimen.** (A) Analysis of the complete test cohort (n=90), consisting of PCR positive  
106 (n=51), PCR negative (n=30) and PCR invalid samples (n=9), reveals an overall sensitivity of

107 29.4% and an overall specificity of 86.7%. 55 samples confirmed symptomatic or  
108 asymptomatic have been divided into (B) PCR positive (n=28) and (C) PCR negative (n=27)  
109 subgroups resulting in sensitivity values off 22.2% (asymptomatic) and 30% (symptomatic)  
110 and specificities of 92.9% (asymptomatic) and 76.9% (symptomatic). BALF= bronchoalveolar  
111 lavage fluid, TW= throat wash, BC=BIOCREDIT Covid-19 Ag test



112

113 **Figure 3: Correlation of SARS-CoV-2 antigen detection with RNA load.** This figure  
114 shows longitudinal SARS-CoV-2 detection by PCR in two asymptomatic individuals. In both  
115 cases SARS-CoV-2 RNA can be detected for about five weeks before recovering in week  
116 six. Antigen is only detected in one individual in three samples with Cts >30 (indicated by  
117 arrows).

118

119

120

121

122

123 References

- 124 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with  
125 Pneumonia in China, 2019. *The New England journal of medicine*. 2020;382(8):727-33.
- 126 2. Fineberg HV. Ten Weeks to Crush the Curve. *The New England journal of medicine*.  
127 2020;382(17):e37.
- 128 3. Smithgall MC, Dowlatshahi M, Spitalnik SL, Hod EA, Rai AJ. Types of Assays for SARS-CoV-2  
129 Testing: A Review. *Laboratory medicine*. 2020;51(5):e59-e65.
- 130 4. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al.  
131 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *The New England journal of*  
132 *medicine*. 2020.
- 133 5. Malecki M, Lusebrink J, Teves S, Wendel AF. Pharynx gargle samples are suitable for SARS-  
134 CoV-2 diagnostic use and save personal protective equipment and swabs. *Infection control and*  
135 *hospital epidemiology*. 2020:1-2.

136